Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson’s Disease
Xiong Zhang(Third People's Hospital of Chengdu), Jian‐Hong Zhu(Northeastern University), Beilei Hu(Wenzhou Medical University), Hongmei Wu(Guangdong Academy of Medical Sciences), Zhiyong He(Albert Einstein College of Medicine), Rui Yang(Tianjin University of Science and Technology), Lili Zhou(Hunan University of Traditional Chinese Medicine), Pengcheng Lu(Nanjing Normal University)
Cited by 77
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Bioavailability of Tea Catechins and Its Improvement
|Molecules|2018|325
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
|Journal of Clinical Oncology|2022|306
Impacts of Early Childhood Education on Medium- and Long-Term Educational Outcomes
|Educational Researcher|2017|282